The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.
Lisa A. Carey
Research Funding - Genentech; GlaxoSmithKline
Donald A. Berry
No relevant relationships to disclose
David Ollila
No relevant relationships to disclose
Lyndsay Harris
No relevant relationships to disclose
Ian E. Krop
No relevant relationships to disclose
Douglas Weckstein
No relevant relationships to disclose
Norah Lynn Henry
No relevant relationships to disclose
Carey K. Anders
No relevant relationships to disclose
Constance Cirrincione
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose
Charles M. Perou
No relevant relationships to disclose
Clifford Hudis
Research Funding - Merck
Other Remuneration - Estee Lauder Company (I)